Clinical trials: Human Papilloma Virus
Papillomavirus Infections
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India.
- Trial name
- NCT00380367
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Papillomavirus Infections, Health Behavior
Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination
This is a minimal risk, anonymous, convenience sample, social behavioral study using qualitative descriptive survey methods. It is to ascertain community member, physician, resident and medical student perspectives regarding…
- Conditions
- Papillomavirus Infections, Health Behavior, Attitude of Health Personnel, Human Papilloma Virus, Male
- Trial name
- NCT02897232
- Testing
- Survey
- Where
- United States
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- Louisiana State University Health Sciences Center Shreveport
Human Papillomavirus
Human Papilloma Virus (HPV) Vaccination Among Rural African American Primary Caregivers and Daughters
African American women living in the rural South are twice as likely as Caucasian women to develop cervical cancer and die of invasive cervical cancer at a higher rate than any other racial/ethnic group in the US (1).
- Trial name
- NCT00937287
- Testing
- There is no intervention in this study.
- Where
- United States
- Volunteers
- 410 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Oropharyngeal Cancer
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
This is a single-center phase 2 study of to test how well the combination of toripalimab with chemotherapy followed by TORS or risk and response stratified de-escalated (chemo)radiotherapy works in patients with in HPV16+…
- Trial name
- NCT07290621
- Testing
- Toripalimab, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Cervical Cancer, Human Papilloma Virus
HPV Vaccine Effectiveness Study in Rwandan Women Living With HIV
Our study will assess and measure population effectiveness of prophylactic HPV vaccine in reducing cervical, anal, and/or oral prevalent and 6-month persistent infections among HPV-vaccinated and 757 HPV-unvaccinated Rwandan WLWH…
- Conditions
- Cervical Cancer, Human Papilloma Virus, Human Immunodeficiency Virus, HPV-Related Carcinoma
- Trial name
- NCT05247853
- Testing
- Blood collection, Oral, cervicovaginal and anal specimen collection, Anoscopy & Biopsy of Acetowhite Lesions
- Where
- Rwanda
- Volunteers
- 3,127 people, healthy volunteers welcome
- Sponsor
- Montefiore Medical Center
Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion
REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)
HPV-303 is a prospective, randomized, double-blind, placebo-controlled study of VGX-3100 delivered intramuscularly (IM) followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed…
- Conditions
- Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion, HSIL
- Trial name
- NCT03721978
- Testing
- VGX-3100, CELLECTRA™-5PSP
- Where
- 53 sites in United States, Argentina and 8 more
- Volunteers
- 203 people
- Sponsor
- Inovio Pharmaceuticals
Infections, Papillomavirus
Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US
This phase 3b study is designed to assess the safety of GlaxoSmithKline Biological's HPV vaccine GSK580299 in female subjects who took part in study 580299/008 and received the control vaccine (Hepatitis A vaccine).
- Trial name
- NCT00799825
- Testing
- GSK Biological's HPV vaccine GSK580299 (Cervarix™)
- Where
- 48 sites in United States, Canada
- Volunteers
- 346 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papilloma Virus (HPV)
Human Papilloma Virus Awareness Intervention
Intervention aimed at increasing knowledge of the human papillomavirus in homosexual men as a means of preventing sexually transmitted diseases and controlling complications associated with the pathology.
- Trial name
- NCT06920589
- Testing
- Safe and Protected Sex" intervention targeting HPV, Diptych of the Secretary of Health in Mexico
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hospital Univeristario Benemerita Universidad Autonoma de Puebla
Nasopharyngeal Carcinoma
The Prognostic Value of Human Papilloma Virus in Nasopharyngeal Carcinoma
It is well established that HPV infection has a casual and is a prognostic factor in several cancer types, including oropharynx. We wish to examine if HPV infection has a prognostic significance in nasopharyngeal carcinoma.
- Trial name
- NCT04014738
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Rambam Health Care Campus
Malignant Tumor of Cervix, Cervical Intraepithelial Neoplasia
Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner
This study evaluates the benefit in women aged from 30 to 65 years, who do not participate to the French opportunistic cervical cancer screening program, of an organized screening with the proposition by the family physician of a…
- Trial name
- PaCUDAHL-Gé (NCT02749110)
- Testing
- Vaginal self-sampling brush
- Where
- France
- Volunteers
- 308 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
HPV
Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment
The occurance and clinical course of human papillomavirus (HPV)-induced lesions is largely determined by the nature of the cellular immune defense generated.
- Trial name
- NCT00941811
- Testing
- Imiquimod
- Where
- Austria
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination
High and Low Resource Interventions to Promote HPV Vaccines
Human Papillomavirus (HPV) is a significant public health issue affecting nearly 14 million people in the United States. HPV can lead to cervical, oropharyngeal, anal, and penile cancers as well as genital warts.The purpose of…
- Conditions
- Human Papilloma Virus, Tdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination, Meningitis, Meningococcal, Communication
- Trial name
- NCT03824093
- Testing
- AFIX Only, AFIX+ Provider Communication Training
- Where
- United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Children's Mercy Hospital Kansas City
Human Papillomavirus
Provider Recommendation and HPV Vaccination
In the United State, there are millions of US teens who are not vaccinated against the human papillomavirus (HPV) putting them at risk of getting HPV-related cancers.
- Trial name
- HPVV (NCT05365048)
- Testing
- Local Tailoring implementation strategy, Prescribed Strategy
- Where
- United States
- Volunteers
- 301,201 people
- Sponsor
- Kaiser Permanente
Cervical Cancer, Cervical Dysplasia
Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study
In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- NCT03813576
- Testing
- Self-collected HPV vaginal swab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
ASC-US, Human Papilloma Virus
Can B12 and Folate Levels Predict HPV Penetration in Patients With ASCUS?
Non-classified atypical squamous cells (ASCUS) is the most common abnormal cervical cytology (%39). The risk of cervical intraepithelial neoplasia 2-3 is 5% and the risk of carcinoma is around 0.1% after diagnosis.
- Trial name
- NCT03903952
- Testing
- Vitamin B12 and folate
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sanliurfa Mehmet Akif Inan Education and Research Hospital
Human Papilloma Virus (HPV)
Usability of HPV Vaccine Reminders
This study will assess the usefulness of parent-targeted strategies in improving care seeking among parents of 11-12 year old adolescents.
- Trial name
- NCT03987490
- Testing
- Text Message, PostCard, Standard of Care
- Where
- United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- University of Florida
Human Papillomavirus Infection
Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV) Vaccine
Human papilloma virus (HPV) is the most common viral infection of the reproductive system and is spread through contact with infected genital skin, mucous membranes, or bodily fluids.
- Trial name
- NCT07888686
- Testing
- 10vHPV, Gardasil9
- Where
- Australia
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Serum Institute of India Pvt. Ltd.
Beliefs, HPV
Evaluation of Educational Interventions Targeting Beliefs About Human Papillomavirus (HPV)
The goal of this clinical trial is to compare the effects of two different educational training programs on beliefs about Human Papillomavirus (HPV) in a group of female hospital employees.
- Conditions
- Beliefs, HPV, Education, Medical, Intervention
- Trial name
- NCT06198491
- Testing
- Misbeliefs about HPV training
- Where
- Turkey (Türkiye)
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Eskisehir Osmangazi University
Condylomata Acuminata
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
This phase Ⅱ clinical study was designed to evaluate the immunogenicity and safety of the novel recombinant HPV type 6/11 bivalent vaccine, manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged 18-55 years…
- Trial name
- NCT02710851
- Testing
- low dosage HPV Vaccine(1:1), low dosage HPV Vaccine(1:2), high dosage HPV Vaccine(1:1)
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Human Papillomavirus-Related Malignant Neoplasm
A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ
This is an open-label and triple cohort study of the safety and efficacy of TALEN and CRISPR/Cas9 to possibly treat HPV Persistency and human cervical intraepithelial neoplasiaⅠwithout invasion.
- Trial name
- NCT03057912
- Testing
- TALEN, CRISPR/Cas9
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital, Sun Yat-Sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.